FERNWOOD FITNESS - PULSE eMagazine - Issue#16 - Flipbook - Page 13
For the past few years,
“longevity” has had a very
particular vibe: biohacking,
leaderboards, and a lot of men
talking about their biological
age. But a correction is
underway, longevity is 昀椀nally
waking up to women!
The reason is simple. Women do not
age like men. Women age differently,
and when you zoom out, that difference
changes what we measure, what we
treat, and when.
Women live longer, but not better
Across countries and income groups,
women generally outlive men. Yet
many women spend a bigger slice of
those extra years managing chronic
conditions, pain, disability, or symptoms
that can take far too long to diagnose.
That is why women’s longevity is
pushing the conversation from lifespan
to healthspan: not just more years, but
more good years.
The ovary is more than fertility, it is a
whole-body signal hub
For decades, the ovary has been
treated like a fertility organ that simply
“昀椀nishes” at midlife. Emerging science
reframes it as an endocrine powerhouse
that helps coordinate signalling across
the body. When ovarian function
declines during perimenopause and
menopause, hormone production drops
sharply, and the ripple effects can be
wide: cardiovascular risk, bone density,
mood, body composition and cognition.
This is also why early menopause
matters. When menopause happens
earlier than expected, it is associated
with higher risks for outcomes like
coronary heart disease and overall
mortality. Menopause is not only
about symptom management. It is a
preventative health moment.
Why the shift is happening now
Three things are colliding.
First, the data gap is harder to
ignore. Women were historically
underrepresented in early-phase
clinical trials, and even when women
were included, sex differences were
not always analysed in ways that help
clinicians make better decisions.
Second, investment is moving.
Women’s health is being reframed
as foundational, medically and
economically.
Third, the science is getting speci昀椀c.
Researchers are increasingly asking:
if ovarian ageing is a key accelerant
of systemic ageing in women, can we
measure it earlier, track it better, and
intervene more precisely?
